70% of People in Singapore Turn to Screens to Escape Daily Pressures, New Study Finds

StarHub launches The Power of Pause to help people build healthier relationships with their digital devices

SINGAPORE, July 6, 2026 /PRNewswire/ -- For many people in Singapore, screens have become a source of comfort, connection and escape. A national study by StarHub and YouGov¹ found that seven in ten people in Singapore use screens to cope with everyday pressures, while more than 80% reported feeling mentally drained by prolonged screen time.²

In response, StarHub today launched The Power of Pause, the next chapter of its Digital Wellbeing initiative. Building on last year's focus on excessive screen time, this year's initiative encourages people to better understand their motivations behind their digital habits and make more intentional choices about when to connect and when to take a break. 

"The conversation around screen time is increasingly about balancing that with creating meaningful, real-life moments with the people around us," said Tan Toi Chia, Chief of People, Organisation and Communications at StarHub. "As our lives become increasingly digital, choosing to pause creates opportunities to strengthen the connection between individuals, families and communities, one moment at a time."

The Power of Pause initiative will run throughout the year through the refreshed Digital BMI (Balanced Media Index) microsite, corporate partnerships, creator collaborations, and community activations, culminating in the return of the StarHub 5G Wellness Festival in September 2026.

A More Personalised Digital BMI Quiz

The refreshed platform combines new tailored recommendations and expert-backed resources from partners including the Infocomm Media Development Authority (IMDA), National Library Board (NLB), and digital mental health platform ThoughtFull. In support of the national Digital for Life movement, IMDA has contributed online safety resources to the platform, focused on helping parents and youths build healthy digital habits.

"The study findings reflect what we see in ThoughtFull's clinical data across the region every day: hyperconnectivity is becoming a measurable driver of psychological strain. Through our partnership with StarHub, Digital BMI users will be able to understand their emotional needs better with clinically backed content and a dedicated support journey within the ThoughtFull app," said Dr John Pinto, Head of Counselling at ThoughtFull.

From digital wellbeing and long-form reading to improve focus, to online safety and parenting in the digital age, the Digital BMI microsite aims to provide trusted guidance tailored to different life stages and needs. 

Visit www.starhub.com/digitalbmi to learn more and discover your Digital BMI today. 

¹ The national survey of 1,036 respondents in Singapore was conducted by StarHub and YouGov in April 2026.
² Please refer to the attached deck for additional findings from the 2025-2026 national studies conducted by StarHub and YouGov. 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

70% of People in Singapore Turn to Screens to Escape Daily Pressures, New Study Finds

SHANGHAI, July 6, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) has welcomed the world's first international patient to begin treatment with Satri-cel, the world's first approved CAR-T therapy for a solid tumor, marking a historic milestone in expanding global access to China's latest oncology innovations.

Josh, a 59-year-old patient from New Zealand with advanced gastroduodenal cancer, travelled to Shanghai after conventional treatment options in his home country became increasingly limited. Following biomarker testing confirming Claudin 18.2 positivity and HER2 negativity, he was deemed eligible for Satri-cel, which is currently available only in China.

After multidisciplinary evaluation and treatment planning at JICC, Josh successfully completed leukapheresis. His CAR-T cells have now entered the manufacturing process, with reinfusion scheduled in the coming weeks.

The milestone comes just days after China's approval of Satri-cel, the first CAR-T therapy in the world approved for the treatment of a solid tumor. The therapy represents a major advance in cellular immunotherapy and further highlights China's growing role in global oncology innovation.

As one of China's leading international cancer centers, JICC has already cared for CAR-T patients from multiple regions of the world and is increasingly serving as a gateway for international patients seeking access to innovative cancer therapies developed in China.

"The approval of Satri-cel represents a historic milestone not only for patients with advanced gastric cancer, but also for the future of oncology worldwide," said Dr. Linli Xuan, Chief of Medical Oncology at Jiahui International Cancer Center. "We are honoured that the world's first international patient has chosen JICC for this groundbreaking treatment. As innovative therapies developed in China continue to gain international recognition, we are seeing growing interest from patients around the world seeking access to these advances. Our commitment is to combine cutting-edge therapies with seamless multidisciplinary care and dedicated international patient support."

Jiahui International Cancer Center offers comprehensive oncology services spanning medical oncology, surgical oncology, radiation oncology, precision medicine and advanced cellular therapies. Through its multidisciplinary care model and dedicated International Patient Office, JICC supports patients worldwide with medical record review, specialist consultations, multilingual coordination, treatment planning, logistics assistance and ongoing follow-up care.

Read the full story here: jiahui.com/en/news/216

Contact Jiahui International Cancer Center:

Email: internationaloffice@jiahui.com

WhatsApp: +852 4619 1904

WeChat: Jiahui-GSN

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

World's First International Patient Begins Treatment with Newly Approved Solid Tumor CAR-T Therapy at Jiahui International Cancer Center